Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics ....Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics of congenital CMV infections, in collaboration with Abbott Diagnostics, and iii) produce an in vivo model of CMV infection to demonstrate the pathogenesis of cellular injury. The combination of molecular expertise at UNSW with monoclonal antibody expertise from Abbott Diagnostics mean this project is unique worldwide.Read moreRead less
Motor problems, ranging from clumsiness to cerebral palsy, are one of the most common adverse outcomes in children born early. This study will investigate the motor development of children born <30 weeks’ gestation compared with peers born at term from birth to 5 years. We will determine whether early clinical evaluations or neuroimaging in the newborn period can predict later motor impairment at 5 years to be able to identify those who will benefit most from early intervention.
Centre Of Research Excellence (CRE) In Newborn Medicine
Funder
National Health and Medical Research Council
Funding Amount
$2,622,320.00
Summary
Problems around birth are common and can have long-term implications, including into adulthood. Our goal is to improve health outcomes for all newborn babies and their families by determining factors that enhance outcome and assessing the benefits and consequences of new treatments for mothers and babies. We are world leaders in this field and are dedicated to training the next generation of health professionals in the care of newborn babies, in Australia and the rest of the world.